Sugi Predict

Sugi Predict / Compounds / SCHEMBL4752565

SCHEMBL4752565

SCHEMBL4752565

CCC(=C(c1ccccc1)c1ccc(OCC[N+](C)(C)[O-])cc1)c1ccccc1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ESR1 P03372 13/20 0.82
▸ CYP19A1 P11511 7/20 0.67
▸ CYP3A4 P08684 4/20 0.67
▸ ESR2 Q92731 8/20 0.64
▸ MAPT P10636 3/20 0.64
▸ CYP1A2 P05177 2/20 0.64
▸ MEN1 O00255 2/20 0.64
▸ TP53 P04637 2/20 0.64
▸ KMT2A Q03164 2/20 0.64
▸ PSMB1 P20618 2/20 0.64
▸ PSMB5 P28074 2/20 0.64
▸ NPC1 O15118 1/20 0.64
▸ NR1I2 O75469 1/20 0.64
▸ PRKD3 O94806 1/20 0.64
▸ ABCB11 O95342 1/20 0.64
▸ EGFR P00533 1/20 0.64
▸ GBA1 P04062 1/20 0.64
▸ NR3C1 P04150 1/20 0.64
▸ ERBB2 P04626 1/20 0.64
▸ PRKCG P05129 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4752564 1.00 ESR1 (0.82) ESR1CYP19A1CYP3A4ESR2MAPT
SCHEMBL6225728 0.95 ESR1 (0.74) ESR1CYP19A1CYP3A4ESR2MAPT
SCHEMBL6227056 0.95 ESR1 (0.74) ESR1CYP19A1CYP3A4ESR2MAPT
SCHEMBL23671979 0.90 ESR1 (1.00) ESR1CYP19A1CYP3A4ESR2MAPT
SCHEMBL21496962 0.90 ESR1 (1.00) ESR1CYP19A1CYP3A4ESR2MAPT
Iodide SCHEMBL30559876 0.89 ESR1 (1.00) ESR1CYP19A1CYP3A4ESR2MAPT
SCHEMBL6227843 0.89 ESR1 (0.65) ESR1CYP19A1CYP3A4ESR2MAPT
SCHEMBL9452012 0.88 ESR1 (0.84) ESR1CYP19A1CYP3A4ESR2MAPT
SCHEMBL6948715 0.84 ESR1 (0.79) ESR1CYP19A1CYP3A4ESR2MAPT
SCHEMBL6947496 0.84 ESR1 (0.79) ESR1CYP19A1CYP3A4ESR2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260083859-A1 SUSTAINED TRANSGENE EXPRESSION OF MODIFIED ERT2 PEPTIDE-SUICIDE PROTEIN FUSION POLYPEPTIDES SENTI BIOSCIENCES INC (US) 2026-03-26 — — US claimed
US-20260022364-A1 ERT2 MUTANTS, INDUCIBLE CELL DEATH SYSTEMS, AND USES THEREOF SENTI BIOSCIENCES INC (US) 2026-01-22 — — US claimed
EP-4658255-A1 SUSTAINED TRANSGENE EXPRESSION OF MODIFIED ERT2 PEPTIDE-SUICIDE PROTEIN FUSION POLYPEPTIDES Senti Biosciences, Inc. (US) 2025-12-10 — — EP claimed
EP-4658677-A2 IMPROVED ERT2 MUTANTS, INDUCIBLE CELL DEATH SYSTEMS, AND USES THEREOF Senti Biosciences, Inc. (US) 2025-12-10 — — EP claimed
WO-2024163908-A2 IMPROVED ERT2 MUTANTS, INDUCIBLE CELL DEATH SYSTEMS, AND USES THEREOF SENTI BIOSCIENCES, INC. (US) 2024-08-08 — — WO claimed
WO-2024163957-A1 SUSTAINED TRANSGENE EXPRESSION OF MODIFIED ERT2 PEPTIDE-SUICIDE PROTEIN FUSION POLYPEPTIDES SENTI BIOSCIENCES, INC. (US) 2024-08-08 — — WO claimed
US-20240226296-A9 ERT2 MUTANTS AND USES THEREOF SENTI BIOSCIENCES, INC. 2024-07-11 — — US claimed
US-20240150433-A1 ERT2 MUTANTS AND USES THEREOF SENTI BIOSCIENCES, INC. 2024-05-09 — — US claimed
US-20240131159-A1 ERT2 MUTANTS AND USES THEREOF SENTI BIOSCIENCES INC (US) 2024-04-25 — — US claimed
EP-4320228-A1 ERT2 MUTANTS AND USES THEREOF Senti Biosciences, Inc. (US) 2024-02-14 — — EP claimed
US-20230405144-A1 INDUCIBLE CELL DEATH SYSTEMS SENTI BIOSCIENCES, INC. 2023-12-21 — — US claimed
CN-116917340-A Inducible cell death system 森迪生物科学公司 2023-10-20 — — CN claimed
EP-4247499-A1 INDUCIBLE CELL DEATH SYSTEMS Senti Biosciences, Inc. (US) 2023-09-27 — — EP claimed
US-20230011052-A1 METHOD AND COMPOSITIONS FOR REGULATED ARMORING OF CELLS SENTI BIOSCIENCES, INC. 2023-01-12 — — US claimed
EP-4072596-A1 METHOD AND COMPOSITIONS FOR REGULATED ARMORING OF CELLS Senti Biosciences, Inc. (US) 2022-10-19 — — EP claimed
WO-2022216825-A1 ERT2 MUTANTS AND USES THEREOF SENTI BIOSCIENCES, INC. (US) 2022-10-13 — — WO claimed
WO-2022216823-A1 ERT2 MUTANTS AND USES THEREOF SENTI BIOSCIENCES, INC. (US) 2022-10-13 — — WO claimed
CN-115087466-A Methods and compositions for regulatory armor of cells 森迪生物科学公司 2022-09-20 — — CN claimed
WO-2022109421-A1 INDUCIBLE CELL DEATH SYSTEMS SENTI BIOSCIENCES, INC. (US) 2022-05-27 — — WO claimed
WO-2008139152-A1 N-OXIDE-CONTAINING PHARMACEUTICAL COMPOUNDS SENTINEL ONCOLOGY LIMITED (GB) 2008-11-20 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260083859-A1 SUSTAINED TRANSGENE EXPRESSION OF MODIFIED ERT2 PEPTIDE-SUICIDE PROTEIN FUSION POLYPEPTIDES ESR1, ESR2, ESRRG ESR1 1/4885CYP19A1 34/4885CYP3A4 1830/4885
US-20230011052-A1 METHOD AND COMPOSITIONS FOR REGULATED ARMORING OF CELLS MYCBP, IKZF3, STAT3 ESR1 3185/4885CYP19A1 4696/4885CYP3A4 4760/4885
US-20260022364-A1 ERT2 MUTANTS, INDUCIBLE CELL DEATH SYSTEMS, AND USES THEREOF ESR2, ESR1, ESRRB ESR1 2/4885CYP19A1 57/4885CYP3A4 2348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.